Systematic review / meta-analysis / 2003
Ephedrine and ephedra modestly increase short-term weight loss but increase adverse symptoms
A meta-analysis of 52 controlled trials assessed ephedra and ephedrine for weight loss. Compared to placebo, monthly weight loss was greater with ephedrine (0.6 kg; 95% CI, 0.2-1.0), ephedrine with caffeine (1.0 kg; 95% CI, 0.7-1.3), ephedra (0.8 kg; 95% CI, 0.4-1.2), and ephedra with caffeine herbs (1.0 kg; 95% CI, 0.6-1.3). Ephedra or ephedrine use was linked to 2.2- to 3.6-fold higher odds of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations.
- Study type
- Systematic review and meta-analysis of controlled trials
- Who was studied
- 52 controlled trials and adverse event reports
- What was measured
- Weight loss, athletic performance, and adverse events
THE PAPER
Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis.
Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, Rhodes SL, Jungvig L, Gagné J. JAMA, 2003.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.